Niagen Bioscience, Inc.
NAGE
$10.10
$0.373.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 107.93M | 99.60M | 91.67M | 85.58M | 83.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 107.93M | 99.60M | 91.67M | 85.58M | 83.17M |
| Cost of Revenue | 40.46M | 38.01M | 35.34M | 33.53M | 32.45M |
| Gross Profit | 67.46M | 61.59M | 56.33M | 52.06M | 50.72M |
| SG&A Expenses | 49.05M | 47.84M | 50.02M | 48.55M | 49.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.70M | 91.87M | 91.22M | 87.89M | 87.53M |
| Operating Income | 13.23M | 7.73M | 447.00K | -2.30M | -4.36M |
| Income Before Tax | 14.58M | 8.86M | 1.49M | -1.35M | -3.53M |
| Income Tax Expenses | 473.00K | 305.00K | -- | -- | -- |
| Earnings from Continuing Operations | 14.11 | 8.55 | 1.49 | -1.35 | -3.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.11M | 8.55M | 1.49M | -1.35M | -3.53M |
| EBIT | 13.23M | 7.73M | 447.00K | -2.30M | -4.36M |
| EBITDA | 14.02M | 8.54M | 1.29M | -1.39M | -3.39M |
| EPS Basic | 0.18 | 0.11 | 0.02 | -0.02 | -0.05 |
| Normalized Basic EPS | 0.12 | 0.07 | 0.01 | -0.01 | -0.03 |
| EPS Diluted | 0.17 | 0.10 | 0.01 | -0.02 | -0.05 |
| Normalized Diluted EPS | 0.11 | 0.07 | 0.01 | -0.01 | -0.03 |
| Average Basic Shares Outstanding | 306.29M | 303.71M | 301.88M | 300.96M | 300.37M |
| Average Diluted Shares Outstanding | 318.24M | 310.24M | 303.69M | 300.97M | 300.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |